Maravai Lifesciences Holdings (MRVI) Net Cash Flow (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Net Cash Flow of -$51.0 million for Q1 2026, down 36.29% year-over-year from -$80.0 million in Q1 2025, and down 91.02% quarter-over-quarter from -$26.7 million in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Net Cash Flow (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$51.0 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 36.29% year-over-year to -$51.0 million; the TTM figure through Mar 2026 stood at -$119.1 million (up 56.97% YoY), while the FY2025 annual figure was -$105.5 million, up 58.24% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$51.0 million, down from -$26.7 million in the prior quarter.
- The five-year high for Net Cash Flow was $119.2 million in Q2 2022, with the low at -$255.8 million in Q4 2024.
- The 5-year median for Net Cash Flow is -$13.3 million (2024), against an average of -$22.7 million.
- Peak annual rise in Net Cash Flow reached 973.2% in 2024, while the deepest fall reached 5408.46% in 2024.
- Maravai Lifesciences Holdings' Net Cash Flow stood at $14.7 million in 2022, then tumbled by 131.6% to -$4.6 million in 2023, then tumbled by 5408.46% to -$255.8 million in 2024, then surged by 89.56% to -$26.7 million in 2025, then slumped by 91.02% to -$51.0 million in 2026.
- Business Quant data shows MRVI's Net Cash Flow at -$51.0 million in Q1 2026, -$26.7 million in Q4 2025, and -$26.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | -95.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -95.36 Mn |
| Jun 30, 2026 | -95.36 Mn |
| Mar 31, 2026 | -51.00 Mn |
| Mar 31, 2026 | -51.00 Mn |
| Dec 31, 2025 | -26.70 Mn |
| Dec 31, 2025 | -26.70 Mn |
| Sep 30, 2025 | -26.33 Mn |
| Sep 30, 2025 | -26.33 Mn |
| Jun 30, 2025 | -15.04 Mn |
| Jun 30, 2025 | -15.04 Mn |
| Mar 31, 2025 | -37.42 Mn |
| Mar 31, 2025 | -37.42 Mn |
| Dec 31, 2024 | -255.76 Mn |
| Dec 31, 2024 | -255.76 Mn |
| Sep 30, 2024 | 4.99 Mn |
| Sep 30, 2024 | 4.99 Mn |
| Jun 30, 2024 | 11.48 Mn |
| Jun 30, 2024 | 11.48 Mn |
| Mar 31, 2024 | -13.27 Mn |
| Mar 31, 2024 | -13.27 Mn |